Skip to content Skip to footer
Subscribe Now
Insight+_Saurabh Chaubey
INSIGHTS+

Most Viewed Articles of 2023

2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.  Top 20 Radiopharma Companies Based on Market Cap Shots: Integrating scintigraphy with…
January 2, 2024

Read more

Exclusive_Todd Zavodnick_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Todd Zavodnick of Dermavant Shares Insight on the Appointment of Nancy Beesley with 25+ Years of Experience

In an interview with PharmaShots, Todd Zavodnick, CEO at Dermavant, shared his views on the addition of Nancy Beesley to its Board of Directors. She brings over 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurological conditions and rare diseasesShots:The addition of Nancy as a board member…
May 9, 2022

Read more

Exclusive_Jeremiah Robison_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Shares Insight on Neural Sleeve for Neurological Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the US FDA’s clearance of Neural Sleeve for patients with cerebral palsy, MS, stroke, and other disordersCionic’s Neural Sleeve has received the US FDA clearance for functional electrical stimulation to assist in gait for patients with foot drop and leg muscle weakness. The lightweight…
March 30, 2022

Read more

Exclusive_John Meduri_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and worldwide. He also shared his views on Accelerate Pheno system and PhenoTest BC kit.Shots:Antibiotic resistance occurs when bacteria develop the ability to defeat…
February 14, 2022

Read more

EXCLUSIVE

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

In an interview with PharmaShots, Moshe Safran, CEO at RSIP Vision shared his views on the new coronary module in the complete 3D reconstruction of the coronary vasculature during angiographyShots:The company reported the 3D reconstruction technology that focused on AI to generate 3D models of patient anatomy from 2D images. The purpose of the technology is to create precise,…
February 7, 2022

Read more

Exclusive_Jeremiah Robison_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jeremiah Robison of Cionic Share Insight on the New Data of Neural Sleeve for Neurological & other Disorders

In an interview with PharmaShots, Jeremiah Robison, Founder, and CEO at Cionic shared his views on the data of the Neural Sleeve gait study for patients with cerebral palsy, MS, stroke, and other neurological disordersShots:Cionic has reported the results from the Neural Sleeve gait study which was conducted in the San Francisco Bay Area. The study showed an…
December 27, 2021

Read more

Exclusive_Dr. Briggs W. Morrison_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Dr. Briggs W. Morrison of Syndax Share Insight on the Syndax’ Agreement with Incyte for Axatilimab

In an interview with PharmaShots, Dr. Briggs W. Morrison, MD, Chief Executive Officer and Director at Syndax share his views on the license agreement for axatilimab with Incyte to treat cGVHD and other fibrotic diseasesShots:The companies collaborated to develop and commercialize Syndax's axatilimab (anti-CSF-1R mAb) & will get a 50:50 US profit shareIncyte will lead the…
November 1, 2021

Read more

Exclusive_Jonathan Benjamin_2021
EXCLUSIVE

Exclusive Interview with PharmaShots: Jonathan Benjamin of Atreca Share Insight on the Data of ATRC-101 to Treat Solid Tumor

In an interview with PharmaShots, Jonathan Benjamin, MD, Ph.D., Senior Vice President & Clinical Research of Atreca shared his views on the initial data from the dose-escalation portion of its ongoing P-Ib trial for ATRC-101 to treat solid tumorShots:The ongoing P-Ib trial evaluates ATRC-101 in patients with solid tumors & 26 patients had been dosed in a trial as of data cut-off…
October 22, 2021

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]